Amgen Inc.AMGNNASDAQ

|||

Overview News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

26 analysts·High coverage

50%

Rating Distribution

Strong Buy

00%

Buy

1350%

Hold

1038%

Sell

312%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see modest upside — consensus target 11% higher.

Bear Case

$304.00

-7%

Consensus

$361.88

+11%

Bull Case

$425.00

+30%

Price Range26 analysts

Low

Consensus

High

$304.00

$425.00

Current Target

Current Price

$326.10

Upside to Target

$35.78

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$22.00(19 analysts)

P/E25x

Current: 25.0x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+2.76%

EPS+4.00%

FY2028

Rev+2.33%

EPS+3.46%

FY2029

Rev+1.67%

EPS+5.30%

Earnings Surprises

Beat rate:92%(11/12 quarters)

Avg surprise:+7.0%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 6, 2026UBS

Amgen assumed at Buy from Neutral at UBS

Target:$380.00

+15.1%from $330.17

Dec 12, 2025Morgan Stanley

Amgen price target lowered to $304 from $329 at Morgan Stanley

Target:$304.00

-4.3%from $317.67

Dec 10, 2025HSBC

Amgen price target raised to $425 from $381 at HSBC

Target:$425.00

+35.4%from $313.85

Dec 3, 2025BMO Capital

Amgen price target raised to $372 from $335 at BMO Capital

Target:$372.00

+9.9%from $338.36

Nov 25, 2025Wells Fargo

Goldman Sachs Reiterates Buy Rating on Amgen (AMGN)

Target:$400.00

+19.7%from $334.30

Nov 24, 2025Truist Financial

Amgen assumed with a Hold at Truist

Target:$318.00

-5.4%from $336.19

Nov 14, 2025Piper Sandler

Amgen (AMGN) PT Raised to $381 at Piper Sandler

Target:$381.00

+14.6%from $332.43

Nov 6, 2025Cantor Fitzgerald

Amgen price target raised to $315 from $305 at Cantor Fitzgerald

Target:$315.00

-1.1%from $318.40

Nov 5, 2025Wells Fargo

Amgen price target raised to $300 from $280 at Wells Fargo

Target:$300.00

+1.1%from $296.70

Aug 25, 2025Piper Sandler

Amgen price target raised to $342 from $328 at Piper Sandler

Target:$342.00

+18.6%from $288.47

May 2, 2025UBS

Amgen price target lowered to $315 from $319 at UBS

Target:$315.00

+12.0%from $281.22

Apr 22, 2025Cantor Fitzgerald

Amgen assumed at Neutral from Overweight at Cantor Fitzgerald

Target:$305.00

+9.6%from $278.40

Mar 5, 2025Johnson Rice

Amgen price target raised to $294 from $275 at BofA

Target:$294.00

-7.1%from $316.57

Nov 12, 2024Jefferies

Jefferies on Amgen (AMGN): 'Thoughts on Phase I bone data for AMG-133 - seems non-issue'

Target:$380.00

+27.2%from $298.84

Nov 12, 2024Cantor Fitzgerald

Cantor Fitzgerald Locates Data on Amgen (AMGN) Hidden in Tables for MariTide's Data

Target:$405.00

+35.5%from $298.84

Oct 21, 2024Morgan Stanley

Morgan Stanley names Amgen 'catalyst-driven idea' into Phase 2 MariTide data

Target:$319.00

+0.7%from $316.74

Oct 16, 2024Goldman Sachs

Goldman Sachs Reiterates Conviction Buy Rating on Amgen (AMGN)

Target:$369.00

+13.5%from $325.09

Oct 7, 2024Barclays

Amgen price target raised to $315 from $300 at Barclays

Target:$315.00

-1.5%from $319.66

Sep 25, 2024BMO Capital

BMO Capital Reiterates Outperform Rating on Amgen (AMGN)

Target:$362.00

+9.4%from $330.92

Sep 25, 2024Raymond James

Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)

Target:$344.00

+4.0%from $330.92

Sep 25, 2024Robert W. Baird

Baird Reiterates Underperform Rating on Amgen (AMGN)

Target:$215.00

-35.0%from $330.92

Aug 7, 2024Wells Fargo

Amgen downgraded to Equal Weight from Overweight at Wells Fargo

Target:$335.00

+1.8%from $328.95

Aug 6, 2024Morgan Stanley

Amgen Gears Up For Q2 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Target:$303.00

-8.4%from $330.79

Jun 14, 2024RBC Capital

Amgen (AMGN) PT Raised to $332 at RBC Capital

Target:$332.00

+11.1%from $298.71

May 17, 2024Oppenheimer

Oppenheimer Reiterates Outperform Rating on Amgen (AMGN)

Target:$380.00

+21.7%from $312.32

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance